Comment from Vanda Pharmaceuticals Inc.

Summary: Vanda Pharmaceuticals Inc. supports the FDA's exploration of drug repurposing and argues that the agency should provide more regulatory flexibility, incentives, and streamlined processes for approving new uses of existing drugs. The company specifically advocates for the approval of its drugs, Hetlioz® and Nereus™, for various unmet medical needs, citing existing clinical evidence and criticizing current regulatory hurdles as barriers to innovation.